Substrate reduction therapy with miglustat for type 1 Gaucher disease: A retrospective analysis from a single institution

Gastrointestinal disturbances and their management in miglustat-treated patients

(2011) Nadia Belmatoug et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study

(2010) Marieke Biegstraaten et al.   BRAIN

The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG)

(2010) P. Chérin et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Treatment of multiple myeloma in patients with Gaucher disease

(2009) Maciej Machaczka et al.   AMERICAN JOURNAL OF HEMATOLOGY

Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

(2009) Carla E.M. Hollak et al.   BLOOD CELLS MOLECULES AND DISEASES

Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project

(2009) P. Giraldo et al.   HAEMATOLOGICA

Miglustat (Zavesca®) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme

(2009) Carla E. M. Hollak et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Changes of Bone Metabolism in Seven Patients with Gaucher Disease Treated Consecutively with Imiglucerase and Miglustat

(2008) P. Mikosch et al.   CALCIFIED TISSUE INTERNATIONAL

Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)

(2008) Kathleen S. Hruska et al.   HUMAN MUTATION

Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III

(2008) J. Cox-Brinkman et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Phenotype, diagnosis, and treatment of Gaucher's disease

(2008) Gregory A Grabowski   LANCET